NORRIS MEDICINES LTD. (NORRIS)

BSE: ₹14.67
Stock Performance
Corporate Announcements
Announcement under Regulation 30 (LODR)-Change in Management

Appointment of Internal Auditor w.e.f 30.05.2026

2026-05-30 16:45:50
Outcome Of Board Meeting Held Today I.E. 30Th May, 2026.

As per attachment.

2026-05-30 16:26:09
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 30Th May, 2026.

As per attachment.

2026-05-30 16:17:42
Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements), 2015 For Holding Board Meeting For Approval Of Audited Financial Results For The Quarter And Year Ended March 31, 2026 And Other Matters.

As per attachment.

2026-05-25 19:39:42
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

As per attachment.

2026-04-20 12:08:21
Closure of Trading Window

As per attachment.

2026-03-26 12:09:18
Outcome Of The Board Meeting Held On 14Th February, 2026 Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.

As per attachment.

2026-02-14 16:41:44
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14Th February, 2026 Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.

As per attachment

2026-02-14 16:34:40
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 – Closure Of Case ID 223728 For Reclassification Of Promoter.

As per attachment.

2026-02-13 18:20:19
Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements, 2015 For Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended December 31St, 2025 And Other Matters.

As per attachment.

2026-02-11 13:28:29

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 0.95 2.56 0.65 1.49 0.72 1.27 1.11 2.72 1.46 3.46 3.27 1.41
YOY Revenue Growth % -0.7% -15.61% -79.57% 22.63% -23.4% -50.36% 71.13% 82.91% 100.94% 172.55% 195.35% -48.24%
Other Income 0.00 0.00 0.00 0.03 0.01 0.00 0.00 0.05 0.02 0.02 0.00 0.02
Total Income 0.95 2.56 0.65 1.52 0.74 1.27 1.11 2.77 1.48 3.48 3.27 1.43
Total Expenses + 1.56 3.03 0.92 1.25 1.10 1.63 1.39 2.94 1.79 4.51 2.57 1.38
Cost of Materials Consumed 1.13 1.28 0.13 0.62 0.55 0.18 1.07 1.45 1.04 3.52 0.07 0.75
Employee Benefit Expense 0.60 0.48 0.34 0.41 0.34 0.29 0.26 0.51 0.41 0.85 0.48 0.33
Other Expenses 0.37 0.30 0.29 0.37 0.37 0.19 0.29 0.37 0.42 0.75 0.42 0.33
Operating Profit -0.61 -0.48 -0.27 0.24 -0.38 -0.36 -0.29 -0.21 -0.33 -1.05 0.70 0.03
OPM % -65% -18.6% -41.9% 15.8% -52.1% -28.6% -25.8% -7.9% -22.9% -30.5% 21.3% 2.1%
Profit Before Tax + -0.61 -0.48 -0.27 0.26 -0.37 -0.36 -0.28 -0.17 -0.31 -1.03 0.70 0.05
Tax Expense 0.00 0.00 0.00 0.09 0.00 0.00 0.00 0.06 0.00 0.00 0.00 0.00
Tax % - - - 33.7% - - - - - - 0% 0%
Profit After Tax -0.61 -0.48 -0.27 0.17 -0.37 -0.36 -0.28 -0.23 -0.31 -1.03 0.70 0.05
EPS (Basic) -0.61 -0.48 -0.27 0.17 -0.37 -0.36 -0.28 -0.23 -0.62 -2.08 0.70 0.05

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Revenue from Operations 8.13 5.82 5.64 8.36 9.44 12.25
YOY Revenue Growth % 39.72% 3.28% -32.57% -11.44% -22.96% -
Other Income 0.05 0.06 0.03 0.01 0.03 0.05
Total Income 8.18 5.88 5.66 8.37 9.46 12.30
Total Expenses + 8.46 7.06 6.76 9.57 11.65 16.29
Cost of Materials Consumed 4.34 3.37 3.16 3.23 3.57 9.53
Employee Benefit Expense 1.67 1.41 1.82 2.30 2.33 3.10
Other Expenses 1.49 1.22 1.34 1.77 1.57 2.15
Operating Profit -0.33 -1.24 -1.13 -1.21 -2.21 -4.04
OPM % -4% -21.3% -20% -14.4% -23.4% -33%
Profit Before Exceptional -0.28 -1.18 -1.10 -1.19 -2.18 -3.99
Exceptional Items 0.00 0.00 0.00 0.00 0.00 0.00
Profit Before Tax + -0.28 -1.18 -1.10 -1.19 -2.18 -3.99
Tax Expense 0.00 0.06 0.09 0.56 1.08 0.97
Tax % - - - - - -
Profit After Tax -0.28 -1.24 -1.19 -1.75 -3.26 -4.96
EPS (Basic) -0.28 -1.24 -1.19 -1.75 -3.26 -4.96

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
ASSETS
Non-Current Assets + 7.08 7.47 8.01 8.77 9.92 11.55
Property, Plant & Equipment 4.79 5.27 5.79 6.47 7.07 7.67
Capital Work in Progress 0.00 0.00 0.00 0.00 0.00 0.00
Non-Current Investments 0.00 0.01 0.01 0.01 0.01 0.01
Goodwill 0.00 0.00 0.00 0.00 0.00 0.00
Other Intangible Assets 0.00 0.42 0.00 0.00 0.00 0.00
Current Assets + 5.81 6.34 6.14 4.92 4.27 8.23
Inventories 3.98 4.13 4.33 3.20 2.42 5.10
Trade Receivables 1.17 1.41 1.07 1.10 1.09 1.79
Cash and Cash Equivalents 0.02 0.04 0.04 0.02 0.02 0.02
Current Investments 0.00 0.00 0.00 0.00 0.00 0.00
LIABILITIES & EQUITY
Total Equity -15.15 -14.87 -13.63 -12.44 -10.69 -7.43
Equity Share Capital 9.93 9.93 9.93 9.93 9.93 9.93
Other Equity -25.07 -24.79 -23.56 -22.37 -20.62 -17.36
Non-Current Liabilities 18.51 18.53 18.59 18.43 18.10 15.52
Current Liabilities 9.53 10.15 9.19 7.70 6.78 11.69
Total Liabilities 28.04 28.68 27.78 26.13 24.88 27.22

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Cash from Operating Activities 0.58 0.36 0.34 1.20 -1.01 1.11
Cash from Investing Activities -0.08 -0.58 0.10 -0.02 -0.09 -0.06
Cash from Financing Activities -0.52 -0.49 -0.20 -1.18 1.10 -1.09
Net Increase/Decrease in Cash -0.02 -0.71 0.23 0.00 0.00 -0.04